PDF(Pubmed)
Abstract：
COVID-19 vaccination has significantly reduced both the morbidity and mortality rates associated with SARS-CoV-2 infection. Vaccines, especially mRNA vaccines, have been proposed in several studies to complicate viral myocarditis. Thus, our systematic and meta-analysis review aims to further investigate the possibility of an association between COVID-19 vaccines and myocarditis. We systematically searched PubMed, Web of Science, Scopus, Ovid, and Google Scholar and did a gray search of other databases using the following keywords and terms: \"Myocarditis (\"Myocarditis\" Mesh) OR \"Chagas Cardiomyopathy\" Mesh) AND \"COVID-19 Vaccines\" Mesh. The studies were limited to only English articles that reported myocardial inflammation or myocarditis associated with COVID-19 vaccines. Pooled risk ratio with its 95% confidence interval was analyzed by RevMan software (5.4) to perform the meta-analysis. Our study included 671 patients from 44 studies with a mean age of 14-40 years. Nevertheless, myocarditis was noted in a mean of (3.227) days, and 4.19 per million vaccination recipients experienced myocarditis. Most cases were clinically presented with manifestations of cough, chest pain, and fever. Laboratory tests revealed increased C-reactive protein, and troponin with all other cardiac markers in most patients. Cardiac magnetic resonance imaging (MRI) revealed late gadolinium enhancement with myocardial edema and cardiomegaly. Also, electrocardiograms revealed ST-segment elevation in most patients. Furthermore, the incidence of myocarditis was statistically significantly lower in the COVID-19 vaccine group as compared with the control group (RR = 0.15, 95% CI = 0.10-0.23, p-value < 0.00001). No significant association was found between COVID-19 vaccines and the incidence of myocarditis. The study\'s findings highlight the importance of implementing evidence-based COVID-19 prevention strategies, such as vaccination, to reduce the public health impact of COVID-19 and its associated complications.
摘要：
COVID-19疫苗接种显着降低了与SARS-CoV-2感染相关的发病率和死亡率。疫苗,特别是mRNA疫苗，已在几项研究中提出使病毒性心肌炎复杂化。因此，我们的系统和荟萃分析综述旨在进一步研究COVID-19疫苗与心肌炎之间的相关性.我们系统地搜索了PubMed,WebofScience,Scopus,奥维德,和谷歌学者，并使用以下关键字和术语对其他数据库进行灰色搜索：\"心肌炎(\"心肌炎\"网格)或\"查加斯心肌病\"网格)和\"COVID-19疫苗\"网格。这些研究仅限于报道与COVID-19疫苗相关的心肌炎或心肌炎的英文文章。采用RevMan软件(5.4)对集合风险比及其95%置信区间进行荟萃分析。我们的研究包括来自44项研究的671名患者，平均年龄为14-40岁。然而，心肌炎在平均（3.227）天，和4.19/百万疫苗接种接受者出现心肌炎.大多数病例临床表现为咳嗽，胸痛,和发烧。实验室检查显示C反应蛋白升高,大多数患者的肌钙蛋白和所有其他心脏标志物。心脏磁共振成像（MRI）显示钆增强晚期，伴有心肌水肿和心脏肥大。此外，大多数患者的心电图显示ST段抬高。此外，与对照组相比,COVID-19疫苗组心肌炎的发生率在统计学上显著降低(RR=0.15,95%CI=0.10-0.23,p值<0.00001).在COVID-19疫苗和心肌炎的发病率之间没有发现显着关联。研究结果强调了实施循证COVID-19预防策略的重要性，如接种疫苗，减少COVID-19及其相关并发症对公共卫生的影响。
